K/I/E/Trust Under Agreement 3/ Sells 9,000 Shares of National Research Corporation (NASDAQ:NRCIA) Stock

National Research Corporation (NASDAQ:NRCIA) major shareholder K/I/E/Trust Under Agreement 3/ sold 9,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $36.50, for a total transaction of $328,500.00. Following the sale, the insider now directly owns 5,626,167 shares of the company’s stock, valued at approximately $205,355,095.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

K/I/E/Trust Under Agreement 3/ also recently made the following trade(s):

  • On Monday, October 30th, K/I/E/Trust Under Agreement 3/ sold 500 shares of National Research Corporation stock. The shares were sold at an average price of $38.00, for a total transaction of $19,000.00.
  • On Friday, October 27th, K/I/E/Trust Under Agreement 3/ sold 13,821 shares of National Research Corporation stock. The shares were sold at an average price of $38.00, for a total transaction of $525,198.00.
  • On Wednesday, October 25th, K/I/E/Trust Under Agreement 3/ sold 2,127 shares of National Research Corporation stock. The stock was sold at an average price of $38.00, for a total transaction of $80,826.00.
  • On Monday, October 23rd, K/I/E/Trust Under Agreement 3/ sold 267 shares of National Research Corporation stock. The stock was sold at an average price of $38.00, for a total transaction of $10,146.00.
  • On Thursday, October 19th, K/I/E/Trust Under Agreement 3/ sold 109,000 shares of National Research Corporation stock. The stock was sold at an average price of $37.00, for a total transaction of $4,033,000.00.

National Research Corporation (NRCIA) opened at $32.35 on Wednesday. National Research Corporation has a 12-month low of $15.75 and a 12-month high of $41.99. The company has a market cap of $679.59, a PE ratio of 45.70 and a beta of 1.70.

TRADEMARK VIOLATION WARNING: This piece of content was reported by Week Herald and is the property of of Week Herald. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://weekherald.com/2017/11/15/national-research-corporation-nrcia-major-shareholder-sells-328500-00-in-stock.html.

Hedge funds have recently made changes to their positions in the stock. Royce & Associates LP raised its position in shares of National Research Corporation by 92.5% in the 2nd quarter. Royce & Associates LP now owns 240,417 shares of the business services provider’s stock valued at $6,467,000 after buying an additional 115,532 shares in the last quarter. Kayne Anderson Rudnick Investment Management LLC raised its position in shares of National Research Corporation by 0.4% in the 2nd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,998,546 shares of the business services provider’s stock valued at $53,761,000 after buying an additional 7,276 shares in the last quarter. Goldman Sachs Group Inc. increased its position in National Research Corporation by 55.6% during the 2nd quarter. Goldman Sachs Group Inc. now owns 19,467 shares of the business services provider’s stock worth $524,000 after purchasing an additional 6,955 shares in the last quarter. Hillsdale Investment Management Inc. acquired a new position in National Research Corporation during the 2nd quarter worth approximately $729,000. Finally, Strs Ohio increased its position in National Research Corporation by 49.6% during the 3rd quarter. Strs Ohio now owns 18,100 shares of the business services provider’s stock worth $682,000 after purchasing an additional 6,000 shares in the last quarter. 29.19% of the stock is owned by institutional investors and hedge funds.

Separately, Zacks Investment Research upgraded shares of National Research Corporation from a “hold” rating to a “buy” rating and set a $33.00 price target on the stock in a research note on Saturday, August 5th.

National Research Corporation Company Profile

National Research Corporation, doing business as NRC Health, is a provider of analytics and insights for healthcare providers, payers and other healthcare organizations. The Company operates through six segments: Experience, The Governance Institute, Market Insights, Transparency, National Research Corporation Canada and Connect.

Receive News & Ratings for National Research Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National Research Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply